216532-43-3

Basic information

• Product Name: (2R,5S)-1-benzyl-2,5-dimethylpiperazine
• Synonyms: (2R,5S)-1-Benzyl-2,5-dimethylpiperazine;(2R,5S)-2,5-Dimethyl-1-benzyl-piperazine;(2R,5S)-Benzyl 2,5-Dimethylpiperazine-1-
• CAS NO: 216532-43-3
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.315
• Mol File: 216532-43-3.mol

Chemical Properties

• Boiling Point: 291.506 °C at 760 mmHg
• Flash Point: 109.461 °C
• Appearance: /
• Density: 0.964 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.516
• PKA: 9.35±0.60(Predicted)
• CAS DataBase Reference: (2R,5S)-1-benzyl-2,5-dimethylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,5S)-1-benzyl-2,5-dimethylpiperazine(216532-43-3)
• EPA Substance Registry System: (2R,5S)-1-benzyl-2,5-dimethylpiperazine(216532-43-3)

Safety Data

• Hazardous Substances Data: 216532-43-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2R,5S)-1-Benzyl-2,5-dimethylpiperazine serves as a valuable building block in the synthesis of various pharmaceutical compounds. Its unique structural properties and biological activities make it a promising candidate for drug development, particularly in the discovery of new therapeutic agents.
Used in Medicinal Chemistry Research:
The study of (2R,5S)-1-Benzyl-2,5-dimethylpiperazine contributes to the advancement of medicinal chemistry by providing insights into its potential applications and mechanisms of action. This knowledge can be utilized to design and develop novel drugs with improved efficacy and safety profiles.
Used in Drug Synthesis:
(2R,5S)-1-Benzyl-2,5-dimethylpiperazine is employed as a key intermediate in the synthesis of pharmaceutical compounds, allowing for the creation of diverse drug candidates with potential therapeutic benefits. Its unique stereochemistry and functional groups facilitate the development of innovative drug molecules with targeted pharmacological properties.

InChI:InChI=1/C13H20N2/c1-11-9-15(12(2)8-14-11)10-13-6-4-3-5-7-13/h3-7,11-12,14H,8-10H2,1-2H3/t11-,12+/m0/s1

Upstream product

• 3138-88-3 (+/-)-trans-2,5-dimethyl-4-benzyl-piperazine 
• 1072102-01-2 (3S,6R)-4-benzyl-3,6-dimethylpiperazine-2,5-dione 
• 100-39-0 benzyl bromide 
• 2815-34-1 2,5-dimethyl-piperazine 
• 100-44-7 benzyl chloride 
• 262295-89-6 (3S,6R)-1-benzyl-3,6-dimethylpiperazine-2,5-dione 

Downstream Products

• 431062-00-9 4-benzyl-2R,5S-dimethyl-piperazine-1-carboxylic acid tert-butyl ester 
• 253801-25-1 C₃₅H₄₅N₃O₃ 
• 253801-16-0 tert-butyl 5-[(R)-[(2S,5R)-4-benzyl-2,5-dimethylpiperazinyl](3-methoxyphenyl)methyl]-1,3-dihydro-2H-isoindole-2-carboxylate 
• 648423-52-3 4-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-2-fluorobenzonitrile 
• 648423-54-5 4-[(2S,5R)-4-benzyl-2,5-dimethylpiperazin-1-yl]-2-methylbenzonitrile 
• 243982-58-3 Nov₃r 
• 262295-87-4 (+)-(2S,5R)-4-(2,5-dimethylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 262295-90-9 (2S,5R)-4-(4-benzyl-2,5-dimethylpiperazin-1-yl)-2-trifluoromethylbenzonitrile 

Relevant articles and documents

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

3-AMINO-PYRROLO[3,4-C] PYRAZOLE- 5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS PKC INHIBITORS

The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B: (A) and (B) wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.

(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6- (trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist

A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)4-[4-cyano-3-(trifluoromethyl)phenyl]-2, 5-dimethyl-N-[6(triflouromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED50 = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.

PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION

The present invention provides piperazine derivatives and methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders.

Cyanophenyl derivative

This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.

Indole-based heterocyclic inhibitors of p38α MAP kinase: Designing a conformationally restricted analogue

p38α Mitogen Activated Protein Kinase (MAP kinase) is an intracellular soluble serine threonine kinase. p38α kinase is activated in response to cellular stresses, growth factors and cytokines such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α). The central role of p38α activation in settings of both chronic and acute inflammation has led efforts to find inhibitors of this enzyme as possible therapies for diseases such as rheumatoid arthritis, where p38α activation is thought to play a causal role. Herein, we report structure-activity relationship studies on a series of indole-based heterocyclic inhibitors that led to the design and identification of a new class of p38α inhibitors.

CYANOPHENYL DERIVATIVES

This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.

Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase

N'-Methyl-N-(4-tert-butyl-1,2,5,6-tetrahydropyridine)thiourea, SDZ048- 619 (1), is a modest inhibitor (IC50 = 180 μM) of pyruvate dehydrogenase kinase (PDHK). In an optimization of the N-methylcarbothioamide moiety of 1, it was discovered that amides with a small acyl group, in particular appropriately substituted amides of (R)-3,3,3-trifluoro-2-hydroxy-2- methylpropionic acid, are inhibitors of PDHK. Utilizing this acyl moiety, herein is reported the rationale leading to the optimization of a series of acylated piperazine derivatives. Methyl substitution of the piperazine at the 2- and 5-positions (with S and R absolute stereochemistry) markedly increased the potency of the lead compound (> 1000-fold). Oral bioavailability of the compounds in this series is good and is optimal (as measured by AUC) when the 4-position of the piperazine is substituted with an electron-poor benzoyl moiety. (+)-1-N-[2,5-(S,R)-Dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R)- 3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (14e) inhibits PDHK in the primary enzymatic assay with an IC50 of 16 ± 2 nM, enhances the oxidation of [14C]lactate into 14CO2 in human fibroblasts with an EC50 of 57 ± 13 nM, diminishes lactate significantly 2.5 h post-oral-dose at doses as low as 1 μmol/kg, and increases the ex vivo activity of PDH in muscle, liver, and fat tissues in normal Sprague-Dawley rats. These PDHK inhibitors, however, do not lower glucose in diabetic animal models.